Summary: Long-term survival of relapsed Wilms' tumor patients is about 40% to 70%. Modern second-line treatment consists of either (a) salvage chemotherapy±radiation therapy (CT) or (b) chemotherapy followed by high-dose chemotherapy and autologous hematopoietic stem cell rescue (ASCR). Here, we conduct an individual patient data meta-analysis on 100 patients collected from 6 studies to determine characteristics that predict survival in relapsed patients who received ASCR therapy. We compare these results with survival data on 118 CT treated patients from 2 recently published studies. Four year overall survival among the combined ASCR treated patients was 54.1% (95% CI: 42.8-64.1%). The ASCR patients who only relapsed in the lungs had higher 4-years survival rates 77.7% (58.6% to 88.8%) than those who relapsed in other locations and/or suffered multiple relapses 41.6% (24.8% to 57.6%). Although lung-only relapse is considered a favorable prognostic factor, there was no clear advantage for the patients treated with salvage chemotherapy. Four-year survival rates among stage I-II patients were about 30% higher with CT than ASCR, but the 2 were comparable for stage III-IV patients. These findings suggest salvage chemotherapy is typically the better choice for relapsed Wilms' tumor patients, ASCR could be considered for stage III-IV patients with a lung-only relapse.
A dvances in therapy have improved the outcome of patients with Wilms' tumor. Currently, about 85% of newly diagnosed patients will be cured and more than half of the patients who relapse will respond to second-line therapy. Despite these advances long-term survival of relapsed patients is only 40% to 70%. [1] [2] [3] Several major Wilms' tumor cooperative study groups including the National Wilms' Tumor Study group in the US, the Medical Research Council in the UK, and the International Society of Pediatric Oncology have reported that 15% of Wilms' tumor patients relapse or are refractory to treatment. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Historically, survival after relapse has been dismal despite short-term responses of 43% to 82% to ifosfamide, carboplatinum, etoposide, and topotecan alone or in combination. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] In 2002, Dome et al 24 reported 5-year survival estimates of 63.6±15.7% for recurrent Wilms' tumor patients treated after 1984. Among these patients, the 5-year survival rate for high-risk patients was 47.6±15.7%.
Relapsed Wilms' tumor patients are currently treated with either chemotherapy±radiation therapy (CT) alone or high-dose chemotherapy followed by autologous stem cell rescue (ASCR). It has been difficult to discern the optimal treatment owing to the limited number of relapsed Wilms' tumor patients. In an attempt to address this problem, we have conducted an individual patient data meta-analysis on 100 ASCR treated, relapsed patients pooled from 6 studies including the European Bone Marrow Transplant Solid Tumor Registry, 2 German Cooperative Wilms' Tumor Studies, 3 Children's Memorial Hospital in the US, 1 French Society of Pediatric Oncology, 25 Pediatrics University Hospital Lund in Sweden, 26 and Associazione Italiana Ematologia Oncolgia Pediatrica. 27 After identifying survival related factors among ASCR treated patients, we compare them with survival rates and predictors among CT treated patients from 2 recently published studies. 28, 29 In addition to treatment type, we considered patient characteristics that may have influenced treatment choice and/ or survival rates, including age, histology, stage, remission status at the time of transplant, site of relapse, and preparative regimen.
MATERIALS AND METHODS
We searched for journal records in PubMed published between 1984 and 2008 using these search terms: treatment of relapsed Wilms' tumor, high-risk Wilms' tumor and auto transplant and Wilms' tumor. We selected articles written in English that included survival data on ASCR treated patients less than 18 years of age. We further selected for patients who had relapsed before ASCR treatment (remission status of at least CR2/PR2), resulting in 100 patients. Demographics and survival information on these patients are provided in Table 1 .
All patients were between the ages of 11 months and 16 years and had similar primary tumor stage, relapse location, time to relapse, and survival characteristics across studies. Radiation data when it was included was completed at primary diagnosis or after relapse to sites of disease recurrence (not shown). The site of relapse was reported by all studies except Garaventa et al 2 that also excluded eventfree survival information. 2 Although patient characteristics and treatment methods were generally similar across studies, there was a notable difference among the choice of preparative regimen. Patients received chemotherapy regimens at original diagnosis that were administered according to National Wilms Tumor Study in the United States or European-based Wilms tumor protocols with 2 CT agents for low-stage (I-II) disease and 3 for high stage (III-IV) favorable histology disease. Chemotherapy treatment at relapse varied among patient groups. We included preparative regimen as an indicator variable with ''MEC'' denoting the 3 drug combination: Melphalan, Etoposide, and Carboplatin and ''non-MEC'' for treatments that did not include all 3 of these drugs.
As we were unable to obtain individual patient data for patients who only received chemotherapy treatment, we compared our ASCR results with summary data from the US National Wilms Tumor Study. 28, 29 We compared confidence intervals for 4-year survival between the 2 treatment types overall and within patient subgroups. In addition to survival rates, we also compared toxicity information between the ASCR and chemotherapy treatments.
Statistics
All statistical analyses were conducted on the ASCR data only, as there was no individual patient data for the CT studies. Overall survival time (OS) was defined by the time from transplant until death owing to any cause or the end of the study period. Event-free survival time (EFS) was defined by the time from transplant until tumor recurrence, death owing to any cause or the end of the study period. The Kaplan-Meier method was used to estimate survival curves for categoric variables. Confidence intervals were estimated using Greenwood variance and the log hazard function and all survival rates were reported with their 95% confidence intervals. Mantel-Haenszel tests were used to test the null hypothesis of equivalent survival curves among category levels. Survival rate estimates and MantelHaenszel tests were done with and without study stratification. In the case in which both P-values are reported, the P-value for the study-stratified analysis is denoted by ''strat.'' Variables that significantly predicted survival in bivariate comparisons were considered for multivariate analysis. Multivariate analyses were done using Cox proportional-hazards models for both OS and EFS outcomes stratified by study. Final models were assessed for compliance with proportional hazards model assumptions using Schoenfeld residual plots and a w 2 test for independence.
RESULTS

Survival Predictors for Autologous Stem Cell Rescue (ASCR) Treatement
Kaplan-Meier overall survival (OS) and EFS curves for the ASCR patients are shown in Figure 1 . The 4-year OS among the 100 patients is 54.1% (42.8% to 64.1%) and Figure 2 . Although there was no statistically significant difference in OS among the studies (P-value=0.145), Figure 2 shows a large spread in 4-year survival rates. Campbell et al (2004) had the highest 4-year survival rate at 76.9% (57.1% to 100%) and Garaventa et al (1994) had the lowest at 41.9% (25.1% to 70%). EFS curves are more comparable among the studies, with 4-year event-free survival rates ranging from 37.5% to 56.6% (P-value=0.892).
Kaplan-Meier curves were constructed for all demographic and clinical variables with and without stratification by study. Site of first relapse, histology, and remission status had a significant effect on survival (Fig. 3) . The 34 patients who relapsed in the lungs had a 4-years survival advantage 77.7% (58.6% to 88.8%) over the 45 patients who relapsed in other sites 41.6% (24.8% to 57.6%). The 82 patients with favorable histology (FH) had a 4-years survival advantage over the 18 patients with unfavorable histology (UH) (60.2%; 47.9% to 70.5% versus 25.4%; 5.8% to 51.6%). Complete response (CR) at time of transplant had an event-free survival advantage over partial response (PR) (P-value=0.007), but this advantage was not significant for overall survival (P-value=0.148).
Patient stage dichotomized as I-II (38 patients) and III-V (62 patients) did not have a statistically significant affect on survival in this data set (Figs. 3G, H) . The 4-year survival rates were 47.2% (27.3% to 64.8%) in the stage I-II group and 57.9% (44.2% to 69.4%) in the stage III-V group.
Multivariate cox proportional hazards models in Table 2 for site of relapse, histology and stage at diagnosis showed that both site of relapse and histology predicted survival (at the 0.10 significance level). Site of relapse was the more important predictor for both models, in which patients who did not have a lung-only relapse were at about 3 times the risk of death or recurrence than patients who relapsed in the lungs alone (hazards ratios were 3.5 and 2.4, respectively). Histology achieved moderate significance in predicting overall survival, in which patients with unfavorable FIGURE 1. Overall and event-free survival curves for autologous hematopoietic stem cell rescue (ASCR) treated patients compiled from 6 studies. Study adjusted survival curves were very similar to the unadjusted curves pictured below. FIGURE 2. Overall and event-free survival curves for 100 autologous hematopoietic stem cell rescue (ASCR) treated patients by study.
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histology had about twice the risk of death in comparison with those with favorable histology. Stage was not a significant predictor for either OS or EFS models. Both models satisfied proportional hazards assumptions.
Survival Rates Among Patients Treated With ASCR Versus Chemotherapy Alone
We compared the results from our meta-analysis of ASCR treated patients with recently published results on CT treated patients from the National Wilms Tumor Study (NWTS)-5. patients combined are presented in Table 3 , along with the corresponding characteristics in the combined ASCR studies. The ASCR and CT treated patients have similar characteristics except for a tendency to treat younger patients who have favorable histology with CT. As a result, we include age and histology adjusted rates when comparing ASCR and CT treatments in Table 4 . Table 4 shows that in the CT studies, there was a 30% 4-year OS advantage for stage I-II patients over stage III-IV patients. In contrast there was no survival advantage for stage in the ASCR studies. Among the ASCR patients, those who had a lung-only (LO) relapse had about a 36% survival advantage over those who relapsed in other sites Rates are reported among (1) all patients, (2) patients who relapsed in the lungs only, (3) all patients adjusting (adj) for age and histology, and (4) patients who relapsed in the lungs only adjusting for age and histology. We present ASCR rates adjusted by age and histology as they differed between the ASCR and CT studies ( Table 3 ). Note that in the ASCR studies patient data was only available on 79 patients for groups 2-4. *We did not control for histology as there was only 1 death in this subgroup. Seventy-nine patients with complete data were included in constructing these models.
(not shown), and a 24% advantage over the survival rate in the patients combined. This advantage was not present in the CT studies in which at best a LO relapse conferred a 3% advantage (in stage III-IV patients). Adjusting for age and histology had little effect on the ASCR survival rates except for a moderate survival increase among the stage III-IV patients.
In most cases, the CT treated patients had comparable or improved 4-year survival over the ASCR treated patients. However, there is suggestive evidence that LO stage III and IV relapse patients may benefit from ASCR, with a 6.5% and 21.7% advantage over CT among the stage I-II and stage III-IV patients, respectively.
Grade 3-4 Toxicity of ASCR Versus Chemotherapy Treatments
In most studies, toxicity information was determined according to National Cancer Institute criteria but the information reported was inconsistent. Overall there was higher rate of serious toxicity among the ASCR patients (Table 5 ). There were 4 toxic deaths among the ASCR treated patients (3.7%) in comparison with 1 toxic death among the chemotherapy patients (0.8%). The CT patients experienced more than twice as many infections as the ASCR treated patients (47% vs. 17%) and had higher pulmonary toxicity.
DISCUSSION
About 15% of Wilms' tumor patients are refractory or relapse after treatment, and relapsed patients are currently treated with chemotherapy alone (CT) or autologous stem cell replacement (ASCR). We carried out an independent patient data meta-analysis on 100 relapsed Wilms' tumor patients treated with ASCR from 6 studies conducted from 1984 to 2006 with 4-year survival rates ranging from 42% to 77%. We estimated a 4-year overall survival rate of 54.1% (42.8% to 64.1%) and a 4-year EFS of 50.0% (37.9% to 60.9%) from all patients combined. Despite the differences in survival rates among the 6 ASCR studies, controlling for study did not have much effect on our results.
Patients treated with ASCR whose secondary relapse was confined to the lungs had a 36% 4-years survival advantage on average over patients who relapsed in other sites (log rank P-value=0.004; 4-year OS=77.7%; 58.6% to 88.8% vs. 41.6%; 24.8% to 57.6%). Similarly, patients with favorable histology enjoyed a 35% survival advantage on average over those with unfavorable histology (log rank P-value=0.01; 4-year OS: 60.2%; 47.9% to 70.5% vs. 25.4%; 5.8% to 51.6%). Surprisingly, patient stage was not a significant predictor of survival in the ASCR studies, with similar 4-year OS and EFS rates between the stage I-II and stage III-IV patients (47.2%; 27.3% to 64.8% and 57.9%; 44.2% to 69.4%). The slight survival advantage for the stage III-IV patients is likely owing to chance variation and the 20% higher frequency of lung-only relapse in this group. Multivariate models confirmed our main findings that a solitary pulmonary relapse was protective (HR=0.288) and stage had a minimal effect on survival. Histology was moderately related to overall survival (P=0.084) with unfavorable histology increasing a patient's risk by a factor of 2.
Stage was the most important predictor of survival in the CT studies, such that the National Wilms Tumor Study (NWTS)-5 data was stratified by stage (I-II and III-IV) and published separately. 28, 29 The survival rate for stage I-II patients treated with CT was about 40% higher than stage III-IV patients treated with CT, but in both studies there was only a small difference in survival for patients who relapsed in the lung-only in comparison to all patients combined.
Stage I-II patients treated with CT had nearly a 35% 4-year survival advantage over ASCR treated patients (81.8%; 66.0% to 90.7% and 47.2%; 27.3% to 64.8%, respectively) whereas the survival rates for these therapies were similar for stage III-IV patients (57.9%; 44.2% to 69.4% and 48.0%; 32.6% to 61.8%, respectively). Interestingly, there is evidence that patients who relapse in the lungs only (LO) may benefit from ASCR. Although the survival rates among the LO stage I-II patients were comparable (ASCR: 87.5%; 38.7% to 98.1% and CT: 81%; 59.9% to 91.7%), there was a 20% survival advantage for LO stage III-IV patients treated with ASCR (74.5%; 51.7% to 87.7% and 52.8%; 29.7% to 71.5%, respectively). Although these results are compelling, we caution that there is potential bias in an observational comparison of CT and ASCR treatments. Although stage was the only trait that notably differed between treatments in our univariate comparisons, treatment decisions may have been based on combinations of these traits. Similarly, there may have been additional unreported characteristics such as disease progression that affected treatment choice. It is possible that these biases explain the survival advantage that we observed in stage III and IV LO relapse patients. However, the potential benefit of ASCR therapy to LO stage III-IV patients warrants further study. All 5 toxicity-related deaths among the 218 relapsed patients were owing to infection. Although the toxic death rate was higher in the ASCR studies (3.7% versus 0.8% in the CT studies), it is worth noting that 3 of the 4 ASCR toxic deaths occurred in the 80's. 2 This perhaps reflects a lower standard of supportive care, as survival rates have improved over the past 2 decades. 27 Acute toxicity in the lungs was more common among CT treated patients than those who received ASCR, which could explain why LO relapse had minimal benefit in the CT studies.
In summary, our results suggest using chemotherapy to treat relapsed patients who were primary stage I-II at diagnosis and considering ASCR therapy for stage III-IV patients whose relapse was confined to the lungs. Although there were more toxic deaths in the ASCR studies, this could be attributed to a lower standard of supportive care given the 1984 to 1991 time frame for these deaths. Further data is warranted to confirm these findings and substantiate the suggested treatment recommendations.
CONCLUSIONS
Relapsed Wilms' tumor patients who are stage I-II at initial diagnosis may benefit from chemotherapy treatment over high-dose chemotherapy, followed by autologous stem cell rescue. Four-year overall survival rates of stage III-IV patients are similar among CT and ASCR treatments, except for patients with a solitary pulmonary relapse in which there seems to be a benefit from ASCR. Stage at initial diagnosis is an important predictor of long-term 6.5% (2) 58% (18) 26% ( All toxicicity-related deaths were owing to infection. NS stands for not specified in the article. Individual patient toxicity data was only available for toxic deaths, but other toxicity information was summarized for most studies. *Toxicity percentages were based on 118 patients except for ''Pulm'' and ''Cardio'' which were not reported in Malogolowkin et al 28 ; and ''Gastro'' and ''Fever'' which were not reported in the chemotherapy studies. wTotal patients included in each study. In this column we include in parentheses the corresponding number of ASCR patients included in our survival analysis.
Specific conditions include: zVeno-Occlusive Disease (VOD).
yGI hemorrhage.
JMucositis.
zVomit and diarrhea. #Tubular dysfunction. **Glomerulare dysfunction.
wwRenal failure. zzCardiomyopathy.
yyPericardial effusion.
JJPneumonia.
survival for chemotherapy treatment, whereas site of relapse, histology, and remission status at the time of transplant predict survival for ASCR therapy.
